CN Stock MarketDetailed Quotes
300254 Shanxi C&Y Pharmaceutical Group
- 9.56
- +0.23+2.47%
Market Closed Nov 5 15:00 CST
2.38BMarket Cap28.62P/E (TTM)
9.57High9.25Low133.74KlotVolume9.30Open9.33Pre Close126.20MTurnover5.94%Turnover Ratio94.65P/E (Static)248.67MShares11.8652wk High3.66P/B2.15BFloat Cap4.9852wk Low11.20Limit Up225.02MShs Float54.40Historical High7.46Limit Down3.43%Amplitude4.72Historical Low--Dividend TTM9.44Avg Price64.57KlotAsk--Div YieldTTM100Lot Size67.95KlotBid
Shanxi C&Y Pharmaceutical Group Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 6.45%608.82M | 9.72%401.11M | 3.44%189.49M | -3.58%799.31M | -9.77%571.94M | -9.72%365.58M | -4.46%183.19M | -10.90%829M | -11.65%633.85M | -11.55%404.96M |
| Operating revenue | 6.45%608.82M | 9.72%401.11M | 3.44%189.49M | -3.58%799.31M | -9.77%571.94M | -9.72%365.58M | -4.46%183.19M | -10.90%829M | -11.65%633.85M | -11.55%404.96M |
| Other operating revenue | ---- | -18.13%1.81M | ---- | 65.81%6.89M | ---- | 4.66%2.2M | ---- | -23.49%4.15M | ---- | -17.98%2.11M |
| Total operating cost | -3.50%563.19M | -4.29%374.47M | -5.33%176.06M | -10.23%803.21M | -11.71%583.64M | -9.40%391.27M | -7.25%185.98M | -10.83%894.75M | -9.16%661.08M | -9.28%431.88M |
| Operating cost | 8.41%200.98M | 8.38%133.68M | 5.24%64.51M | 2.62%257.47M | -3.16%185.38M | 1.04%123.34M | 11.43%61.29M | -11.09%250.89M | -7.24%191.44M | -13.16%122.06M |
| Operating tax surcharges | -4.72%7.6M | 4.53%4.45M | -32.55%1.59M | 4.76%12.79M | 1.82%7.98M | -13.82%4.26M | -5.54%2.35M | -5.26%12.21M | -13.53%7.84M | -9.02%4.94M |
| Operating expense | -8.19%220.25M | -10.52%145.17M | -12.54%66.77M | -20.51%331.95M | -22.32%239.9M | -20.01%162.25M | -19.00%76.35M | -12.83%417.58M | -13.03%308.82M | -11.79%202.83M |
| Administration expense | 1.00%86.43M | -1.23%55M | 6.19%27.41M | 4.26%121.49M | 1.23%85.58M | -3.66%55.68M | -8.98%25.81M | -6.71%116.52M | -2.12%84.54M | 6.86%57.8M |
| Financial expense | -54.83%11.62M | -66.15%7.62M | -66.73%3.74M | -31.34%29.54M | -19.38%25.73M | 6.02%22.52M | 2.63%11.25M | -8.98%43.02M | 7.99%31.91M | 13.62%21.24M |
| -Interest expense (Financial expense) | -54.14%12.34M | -66.37%8.17M | -64.26%4.11M | -28.02%33.16M | -19.99%26.91M | 7.33%24.29M | 2.20%11.5M | -6.32%46.06M | 8.29%33.63M | 14.14%22.63M |
| -Interest Income (Financial expense) | 74.46%-833.31K | 65.66%-635.18K | 55.17%-319.29K | -46.69%-3.74M | -96.32%-3.26M | -114.54%-1.85M | -98.43%-712.22K | -21.39%-2.55M | -1.09%-1.66M | 28.32%-862.15K |
| Research and development | -7.06%36.31M | 22.91%28.55M | 34.95%12.05M | -8.35%49.97M | 6.94%39.07M | 0.94%23.23M | -5.52%8.93M | -4.55%54.52M | -11.48%36.54M | -15.83%23.01M |
| Credit Impairment Loss | -1,496.01%-2.5M | -244.03%-940.63K | 134.55%479.32K | 212.62%3M | 109.56%178.85K | 162.22%653.1K | 8.94%-1.39M | -150.14%-2.67M | -189.75%-1.87M | -373.03%-1.05M |
| Asset Impairment Loss | -5,074.65%-1.95M | -59.91%179.28K | 172.79%1.21M | 86.50%-6.55M | -99.48%39.13K | -91.09%447.23K | -90.80%445.4K | -23.15%-48.52M | 471.40%7.54M | 13,024.77%5.02M |
| Other net revenue | 236.64%16.08M | 415.95%14.71M | 2,629.05%5.01M | 189.30%44.06M | -50.96%4.78M | -57.72%2.85M | -94.72%183.43K | -652.53%-49.34M | -40.25%9.74M | -59.31%6.74M |
| Invest income | 1,536.27%3.86M | 88.98%-29.33K | ---- | 708.66%20.88M | 178.67%236.01K | -3,728,905.88%-266.24K | 99.48%-1.56K | -125.16%-3.43M | -105.74%-299.99K | -100.00%7.14 |
| -Including: Investment income associates | -112.43%-29.33K | 88.98%-29.33K | ---- | 708.66%20.88M | 178.67%236.01K | -3,728,905.88%-266.24K | 99.48%-1.56K | -142.41%-3.43M | 5.68%-299.99K | 100.04%7.14 |
| Asset deal income | 20,197.65%7.41M | 34,199.39%7.42M | 1,077.45%44.12K | 2,643.49%18.8M | -106.26%-36.85K | -103.61%-21.77K | -208.68%-4.51K | 283.68%685.19K | 431.77%589.16K | 444.49%603.25K |
| Other revenue | 112.25%9.25M | 296.16%8.08M | 188.78%3.27M | 72.98%7.93M | 15.49%4.36M | -5.97%2.04M | 150.12%1.13M | -67.84%4.58M | -65.39%3.77M | -79.37%2.17M |
| Operating profit | 991.33%61.7M | 281.05%41.35M | 805.64%18.44M | 134.89%40.15M | 60.42%-6.92M | -13.16%-22.84M | 50.82%-2.61M | -44.64%-115.09M | -390.55%-17.49M | -1,122.55%-20.18M |
| Add:Non operating Income | 4.20%12.78M | -2.83%9.77M | -5.04%7.66M | -34.22%16.75M | -43.09%12.26M | -47.37%10.05M | -37.49%8.06M | 52.07%25.47M | 43.52%21.54M | 61.09%19.1M |
| Less:Non operating expense | -14.24%1.07M | -59.49%488.41K | -89.73%47.75K | 314.22%1.63M | 136.29%1.25M | 640.31%1.21M | 1,432.88%465.11K | -85.20%392.63K | -78.59%528.79K | -89.33%162.86K |
| Total profit | 1,695.63%73.41M | 461.91%50.63M | 422.31%26.05M | 161.41%55.28M | 15.92%4.09M | -1,025.81%-13.99M | -34.02%4.99M | -37.48%-90.02M | -81.00%3.53M | -114.31%-1.24M |
| Less:Income tax cost | 65.40%6.25M | -58.79%1.55M | -45.12%1.1M | -17.04%6.55M | -40.92%3.78M | -11.10%3.75M | -45.90%2.01M | -12.90%7.9M | -46.36%6.39M | 67.99%4.22M |
| Net profit | 21,558.15%67.16M | FLtoP49.09M | 736.80%24.95M | FLtoP48.73M | FLtoP310.08K | FPtoL-17.74M | -22.58%2.98M | FPtoL-97.92M | SL-2.87M | SL-5.46M |
| Net profit from continuing operation | 21,558.15%67.16M | 376.65%49.09M | 736.80%24.95M | 149.76%48.73M | 110.81%310.08K | -224.73%-17.74M | -22.58%2.98M | -31.35%-97.92M | -143.20%-2.87M | -188.57%-5.46M |
| Less:Minority Profit | 64.30%23.01M | 144.28%15.58M | 29.65%6.66M | 14.22%23.53M | -37.78%14M | -63.26%6.38M | -4.69%5.14M | 21.96%20.6M | 87.12%22.5M | 68.76%17.36M |
| Net profit of parent company owners | 422.48%44.15M | 238.89%33.5M | 947.75%18.28M | 121.26%25.2M | 46.04%-13.69M | -5.68%-24.12M | -40.00%-2.16M | -29.62%-118.52M | -370.94%-25.37M | -454.21%-22.83M |
| Earning per share | ||||||||||
| Basic earning per share | 422.22%0.1827 | 238.98%0.1387 | 950.56%0.0757 | 120.86%0.1043 | 47.35%-0.0567 | -1.63%-0.0998 | -30.88%-0.0089 | -24.63%-0.4999 | -356.36%-0.1077 | -442.54%-0.0982 |
| Diluted earning per share | 422.22%0.1827 | 238.98%0.1387 | 950.56%0.0757 | 120.86%0.1043 | 47.35%-0.0567 | -1.63%-0.0998 | -30.88%-0.0089 | -24.63%-0.4999 | -356.36%-0.1077 | -442.54%-0.0982 |
| Other composite income | ||||||||||
| Total composite income | 21,558.15%67.16M | 376.65%49.09M | 736.80%24.95M | 149.76%48.73M | 110.81%310.08K | -224.73%-17.74M | -22.58%2.98M | -31.35%-97.92M | -143.20%-2.87M | -188.57%-5.46M |
| Total composite income of parent company owners | 422.48%44.15M | 238.89%33.5M | 947.75%18.28M | 121.26%25.2M | 46.04%-13.69M | -5.68%-24.12M | -40.00%-2.16M | -29.62%-118.52M | -370.94%-25.37M | -454.21%-22.83M |
| Total composite income of minority owners | 64.30%23.01M | 144.28%15.58M | 29.65%6.66M | 14.22%23.53M | -37.78%14M | -63.26%6.38M | -4.69%5.14M | 21.96%20.6M | 87.12%22.5M | 68.76%17.36M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
% Chg
No Data